February 22 | 2024

2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024

Read more
February 12 | 2024

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Read more
February 12 | 2024

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)

Read more
January 4 | 2024

2cureX announces changes to the Board of Directors.

Read more
December 29 | 2023

2cureX announces changes to the management

Read more
December 6 | 2023

2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial

Read more
November 23 | 2023

2cureX publishes interim report for the third quarter of 2023

Read more
November 14 | 2023

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMAN I 2CUREX AB (PUBL)

Read more
November 14 | 2023

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

Read more
November 10 | 2023

IndiTreat® Image Uploader gets IVD CE-Mark

Read more
October 30 | 2023

2cureX participated in “Knæk Cancer” panel discussion.

Read more
October 26 | 2023

Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation

Read more
October 25 | 2023

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Read more
October 25 | 2023

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)

Read more
October 11 | 2023

2cureX advances towards IVD-R compliance by securing a contract with a Notified Body

Read more
October 3 | 2023

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).

Read more
August 30 | 2023

2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation

Read more
August 24 | 2023

2cureX publishes interim report for Q2 2023

Read more